Milestones
- Licensed from Jiangsu HengruiOct 2024Complete.
- Phase 2 efficacy data released (17.7% weight loss at 48 weeks)Jul 2025Complete.
- Phase 3 KaiNETIC enrollment startsTarget Jan 2026Current milestone.
- Phase 3 data expectedTarget 2028Not yet reached.
Most important updates
- Kailera closes $600 million Series B led by Bain Capital, bringing total funding to over $1 billion14 Oct 2025
- Ribupatide Phase 2 data shows 17.7% mean weight loss at 48 weeks across all doses versus placeboJul 2025
- Kailera Therapeutics launches with $400 million Series A and exclusive license to ribupatide from Jiangsu Hengrui14 Oct 2024
Upcoming
- Jan 2026Phase 3 KaiNETIC enrollment starts (next)
- 2027Phase 3 data readout (expected 2028)
- 2028Phase 3 data expected